Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients.

ABSTRACT: Clopidogrel, an antiplatelet drug, is frequently prescribed to patients diagnosed with ischemic diseases such as those suffering from acute coronary syndromes or ischemic stroke. Despite the drug being effective in majority of the patients, some still experience ischemic events early in the treatment which might be due to poor platelet inhibition. This study aims to investigate the association of cytochrome P450 2C19 (CYP2C19) loss-of-function polymorphisms, haplotypes as well as a wide range of clinical and demographic variables with platelet aggregation phenotypes to clopidogrel in a Pakistani cohort. The study comprised of a total of 120 patients diagnosed with cardiovascular diseases and were treated with clopidogrel. Antiplatelet response to clopidogrel was monitored by Helena AggRAM

SUBMITTER: Ahmed S 

PROVIDER: S-EPMC9007971 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature